MCID: NRC002
MIFTS: 62

Narcolepsy malady

Categories: Rare diseases, Neuronal diseases, Mental diseases, Genetic diseases

Aliases & Classifications for Narcolepsy

Aliases & Descriptions for Narcolepsy:

Name: Narcolepsy 12 50 25 51 52 42 14 69
Narcolepsy-Cataplexy Syndrome 50 56 29 69
Narcoleptic Syndrome 50 25
Gelineau Syndrome 50 25
Paroxysmal Sleep 12 50
Narcolepsy, Without Cataplexy 12
Narcolepsy Without Cataplexy 56
Gelineau's Syndrome 50
Gélineau Disease 56

Characteristics:

Orphanet epidemiological data:

56
narcolepsy-cataplexy syndrome
Prevalence: 1-5/10000 (Europe),1-5/10000 (Norway),1-5/10000 (Finland),1-5/10000 (China); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;
narcolepsy without cataplexy
Prevalence: 1-5/10000 (United States); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:8986
ICD9CM 35 347.0
MeSH 42 D009290
NCIt 47 C84489
ICD10 via Orphanet 34 G47.4
MESH via Orphanet 43 D009290
UMLS via Orphanet 70 C0027404 C0751362
UMLS 69 C0027404

Summaries for Narcolepsy

NINDS : 51 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleeep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience irresistable bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms ofcataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis . The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including syncope, obesity and hallucinations. An important gene associated with Narcolepsy is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways are HTLV-I infection and Toxoplasmosis. The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotype is nervous system.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference : 25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases : 50 narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. people with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). the disorder is usually sporadic but some cases are familial. there is no cure, but some symptoms can be managed with medicines and lifestyle changes. last updated: 4/27/2015

Wikipedia : 71 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 2 Narcolepsy 7
Narcolepsy 5 Narcolepsy 1
Narcolepsy 6 Narcolepsy 3
Narcolepsy 4 Narcolepsy Risk Factor

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 narcolepsy 1 12.4
2 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 12.2
3 narcolepsy 7 12.2
4 narcolepsy 2 11.9
5 narcolepsy 3 11.8
6 narcolepsy 5 11.8
7 narcolepsy 6 11.8
8 narcolepsy 4 11.8
9 narcolepsy risk factor 11.7
10 idiopathic hypersomnia 11.3
11 hypersomnia 11.3
12 sleep disorder 11.2
13 imaizumi kuroki syndrome 10.4 HCRT HLA-DQB1
14 autosomal dominant intermediate charcot-marie-tooth 10.4 HLA-DQB1 HLA-DRB1 TNF
15 rud syndrome 10.4 HCRT HCRTR1 HCRTR2
16 distal trisomy 14q 10.4 HLA-DQB1 HLA-DRB1 TNF
17 hemoglobin d disease 10.4 HLA-DQA1 HLA-DQB1 HLA-DRB1
18 clostridium difficile colitis 10.4 HLA-DQB1 HLA-DRB1 TNF
19 osteogenesis imperfecta congenita, microcephaly, and cataracts 10.4 HLA-DQA1 HLA-DQB1
20 cryptococcosis 10.4 HLA-DQB1 HLA-DRB1 TNF
21 myopathy, distal, with early respiratory failure, autosomal dominant 10.4 COMT HCRT HLA-DQB1
22 oromandibular dystonia 10.4 HLA-DQA1 HLA-DQB1 HLA-DRB1
23 migraine with aura 10.4 HLA-DQA1 HLA-DQB1 TNF
24 kernicterus due to isoimmunization 10.4 HLA-DQA1 HLA-DRB1 TNF
25 bickerstaff brainstem encephalitis 10.4 HLA-DQA1 HLA-DQB1 HLA-DRB1
26 niemann-pick disease 10.4 HCRT HLA-DRB1 MOG
27 low anorectal malformation 10.4 HLA-DQB1 HLA-DRB1 TNF
28 choreatic disease 10.4 HCRT HLA-DQB1 HLA-DRB1 TNF
29 hodgkin's paragranuloma 10.4 HCRT HLA-DQB1
30 lyme disease - neurological complications 10.4 HCRT HCRTR1 HLA-DQB1 HLA-DRB1
31 ragweed sensitivity 10.4 HLA-DQA1 HLA-DQB1 HLA-DRB1
32 parasitic helminthiasis infectious disease 10.4 HLA-DQB1 HLA-DRB1 MOG TNF
33 infantile hypotonia 10.4 HCRTR2 HLA-DQB1 TNF
34 apple allergy 10.4 HLA-DQB1 HLA-DRB1
35 bilateral parasagittal parieto-occipital polymicrogyria 10.4 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
36 pulmonary hemosiderosis 10.4 HLA-DRB1 MOG TNF
37 peripheral artery disease 10.4 HLA-DQA1 HLA-DRB1 TNF
38 cervical adenoid basal carcinoma 10.4 HCRT HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
39 nystagmus, congenital motor, autosomal recessive 10.4 HLA-DRB1 LEP TNF
40 immune deficiency, familial variable 10.4 HLA-DQB1 HLA-DRB1
41 advanced sleep phase syndrome, familial, 1 10.4 HLA-DQB1 HLA-DRB1 MOG TNF
42 epithelioid type angiomyolipoma 10.4 ATXN3 HCRT MOG TNF
43 limb ischemia 10.4 HCRT LEP TNF
44 diabetic encephalopathy 10.3 HCRT LEP TNF
45 lin-gettig syndrome 10.3 HLA-DQB1 HLA-DRB1
46 breast hemangiopericytoma 10.3 HCRT HCRTR1 HCRTR2 LEP MOG
47 erythematosquamous dermatosis 10.3 HLA-DQB1 HLA-DRB1 TNF
48 mirizzi syndrome 10.3 HLA-DRB1 TNF
49 t-cell prolymphocytic leukemia 10.3 HLA-DQB1 TNF
50 midline interhemispheric variant of holoprosencephaly 10.3 HLA-DQB1 HLA-DRB1

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

Human phenotypes related to Narcolepsy:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 syncope 56 32 Occasional (29-5%) HP:0001279
2 obesity 56 32 Occasional (29-5%) HP:0001513
3 hallucinations 56 32 Very frequent (99-80%),Very frequent (99-80%) HP:0000738
4 abnormality of vision 56 32 Frequent (79-30%) HP:0000504
5 slurred speech 56 32 Occasional (29-5%) HP:0001350
6 insomnia 56 32 Very frequent (99-80%) HP:0100785
7 excessive daytime sleepiness 56 32 Very frequent (99-80%) HP:0002189
8 cataplexy 56 32 Very frequent (99-80%) HP:0002524
9 transient global amnesia 56 32 Very frequent (99-80%) HP:0010534
10 excessive daytime somnolence 32 HP:0001262
11 sleep disturbance 56 Very frequent (99-80%),Very frequent (99-80%)
12 behavioral abnormality 56 Occasional (29-5%)
13 abnormality of the eye 56 Frequent (79-30%)
14 somnolence 56 Very frequent (99-80%)
15 abnormal rapid eye movement (rem) sleep 56 Frequent (79-30%)
16 abnormal rapid eye movement sleep 32 HP:0002494

UMLS symptoms related to Narcolepsy:


hemiplegia, sleep disturbances, excessive daytime somnolence, sleeplessness, sluggishness

MGI Mouse Phenotypes related to Narcolepsy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.36 MOG TNF ZNF365 ATXN3 COMT DNMT1

Drugs & Therapeutics for Narcolepsy

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
3
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
4
Sodium oxybate Approved Phase 4,Phase 3,Phase 2,Phase 1 502-85-2 5360545
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Rasagiline Approved Phase 4 136236-51-6 3052776
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
9 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
10 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
14 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Phase 1
16 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Tranquilizing Agents Phase 4
18 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
19 Vaccines Phase 4
20 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1
21 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
22 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Pharmaceutical Solutions Phase 4,Phase 3
24 Anti-Anxiety Agents Phase 4
25 Protective Agents Phase 4,Phase 1,Phase 2
26 Psychotropic Drugs Phase 4
27 Autonomic Agents Phase 4,Phase 2,Phase 1
28 calcium channel blockers Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Excitatory Amino Acids Phase 4
31 Anticonvulsants Phase 4
32 Antimanic Agents Phase 4
33 Calcium, Dietary Phase 4,Phase 1,Phase 2
34 Antiparkinson Agents Phase 4
35 interferons Phase 4
36 Dopamine agonists Phase 4
37 Neuroprotective Agents Phase 4
38 Interferon-alpha Phase 4
39 Antioxidants Phase 4
40
Morphine Approved, Investigational Phase 3 57-27-2 5288826
41
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
42
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
43
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
44
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
46 Narcotics Phase 3
47 Analgesics, Opioid Phase 3
48
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
49 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 1
50 Histamine H3 Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 93)
id Name Status NCT ID Phase
1 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4
2 Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription Completed NCT00244465 Phase 4
3 Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS Completed NCT00118378 Phase 4
4 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4
5 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4
6 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4
7 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997 Phase 4
8 Xyrem and Brain Dopamine in Narcolepsy Recruiting NCT02637076 Phase 4
9 Pain Expectations in Subjects With Osteoarthritis Recruiting NCT02155257 Phase 4
10 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4
11 Armodafinil for Patients Starting Hepatitis C Virus Treatment Terminated NCT01470651 Phase 4
12 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4
13 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3
14 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3
15 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3
16 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3
17 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3
18 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy Completed NCT00132873 Phase 3
19 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3
20 Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Completed NCT01399606 Phase 3
21 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3
22 Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients Completed NCT00049803 Phase 3
23 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3
24 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3
25 Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3
26 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3
27 Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Completed NCT01067235 Phase 3
28 Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Completed NCT01789398 Phase 3
29 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Completed NCT01800045 Phase 3
30 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3
31 Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3
32 Modafinil in Cancer Related Fatigue Completed NCT01440621 Phase 3
33 Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Recruiting NCT02720744 Phase 3
34 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Recruiting NCT03030599 Phase 3
35 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Active, not recruiting NCT02348593 Phase 3
36 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT02221869 Phase 3
37 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Active, not recruiting NCT02348606 Phase 3
38 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Enrolling by invitation NCT02348632 Phase 3
39 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3
40 A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Completed NCT00424931 Phase 2
41 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2
42 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Completed NCT01006122 Phase 2
43 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2
44 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2
45 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2
46 Methylphenidate and Parkinson's Disease Completed NCT00359723 Phase 2
47 Sodium Oxybate in Schizophrenia With Insomnia Completed NCT00594256 Phase 2
48 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2
49 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2
50 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence Completed NCT00469508 Phase 2

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Genetic tests related to Narcolepsy:

id Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy 29

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

39
Brain, Eye, Testes, T Cells, Amygdala, Heart, Skin

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 822)
id Title Authors Year
1
Perioperative risks of narcolepsy in patients undergoing general anesthesia: A case-control study. ( 28433385 )
2017
2
Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. ( 28364500 )
2017
3
Pituitary Macrotumor Causing Narcolepsy-Cataplexy in a Dachshund. ( 28090682 )
2017
4
Update on the treatment of narcolepsy: clinical efficacy of pitolisant. ( 28490912 )
2017
5
Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. ( 28522102 )
2017
6
New developments in the management of narcolepsy. ( 28424564 )
2017
7
Rare missense mutations in P2RY11 in narcolepsy with cataplexy. ( 28460015 )
2017
8
Sleep-wake patterns, non-rapid eye movement, and rapid eye movement sleep cycles in teenage narcolepsy. ( 28449905 )
2017
9
The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. ( 28472332 )
2017
10
Comorbidity of narcolepsy with cataplexy and transverse myelitis: aA common autoimmune background? A case report. ( 28449899 )
2017
11
Sleep-wake stability in narcolepsy patients with normal, low and unmeasurable hypocretin levels. ( 28522076 )
2017
12
Cardiovascular fitness in narcolepsy is inversely related to sleepiness and the number of cataplexy episodes. ( 28522101 )
2017
13
Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported measures. ( 28366326 )
2017
14
Narcolepsy drug could help food addicts lose weight. ( 28075285 )
2017
15
Sleep spindle density in narcolepsy. ( 28522097 )
2017
16
Irish MP calls for key documents on Pandemrix to be handed to lawyers representing children with narcolepsy. ( 28428181 )
2017
17
Spectral electroencephalography profile of rapid eye movement sleep at sleep onset in narcolepsy type 1. ( 27905666 )
2017
18
Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. ( 28449892 )
2017
19
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
20
a91Pitolisant for narcolepsy. ( 28087755 )
2017
21
Pharmacological management of narcolepsy with and without cataplexy. ( 28443381 )
2017
22
Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2A years of follow-up. ( 27995693 )
2017
23
The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. ( 28449891 )
2017
24
Rewiring brain circuits to block cataplexy in murine models of narcolepsy. ( 28445807 )
2017
25
Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. ( 28507129 )
2017
26
Nocturnal Dynamics of Sleep-Wake Transitions in Patients With Narcolepsy. ( 28364512 )
2017
27
Narcolepsy Following Yellow Fever Vaccination: A Case Report. ( 27559330 )
2016
28
Diagnostic delay in narcolepsy type 1: combining the patients' and the doctors' perspectives. ( 27149919 )
2016
29
Psychosocial Profile and Quality of Life in Children With Type 1 Narcolepsy: A Case-Control Study. ( 27166243 )
2016
30
Post Tick-Borne Encephalitis Virus Vaccination Narcolepsy with Cataplexy. ( 27397572 )
2016
31
Environmental factors in the etiology of type 1 diabetes, celiac disease, and narcolepsy. ( 27411439 )
2016
32
CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. ( 27621438 )
2016
33
Mechanistic insights into influenza vaccine-associated narcolepsy. ( 27031682 )
2016
34
Altered Brain Microstate Dynamics in Adolescents with Narcolepsy. ( 27536225 )
2016
35
Autoantibody targets in vaccine-associated narcolepsy. ( 27206786 )
2016
36
A systematic review of cognitive function and psychosocial well-being in school-age children with narcolepsy. ( 28065388 )
2016
37
Hypocretin-1 Levels Associate with Fragmented Sleep in Patients with Narcolepsy Type 1. ( 26856902 )
2016
38
Circadian Rest-Activity Rhythm in Pediatric Type 1 Narcolepsy. ( 27091539 )
2016
39
Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1. ( 26757307 )
2016
40
A Global View on Narcolepsy - A Review Study. ( 27488584 )
2016
41
Narcolepsy with cataplexy in a child with Charcot-Marie-Tooth disease. Case Report. ( 27857041 )
2016
42
Improved vigilance after sodium oxybate treatment in narcolepsy: a comparison between in-field and in-laboratory measurements. ( 26909768 )
2016
43
Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. ( 27647645 )
2016
44
Disrupted Sleep in Narcolepsy: Exploring the Integrity of Galanin Neurons in the Ventrolateral Preoptic Area. ( 26951397 )
2016
45
Temporal changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( 27634795 )
2016
46
Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis. ( 27143278 )
2016
47
Efficiency of a Combination of Pharmacological Treatment and Nondrug Interventions in Childhood Narcolepsy. ( 27564079 )
2016
48
Autosomal Dominant Cerebellar Ataxia, Deafness, and Narcolepsy (ADCA-DN) Associated With Progressive Cognitive and Behavioral Deterioration. ( 27869457 )
2016
49
Narcolepsy and influenza vaccination-the inappropriate awakening of immunity. ( 27867997 )
2016
50
Clinical course of H1N1-vaccine-related narcolepsy. ( 27198942 )
2016

Variations for Narcolepsy

Copy number variations for Narcolepsy from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF TNFSF4
2 chemical synaptic transmission GO:0007268 9.78 ATXN3 HCRT HCRTR1 HCRTR2
3 neuropeptide signaling pathway GO:0007218 9.73 HCRT HCRTR1 HCRTR2
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.71 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 T cell costimulation GO:0031295 9.67 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.58 HCRT HCRTR2 P2RY11
8 response to peptide GO:1901652 9.57 HCRTR1 HCRTR2
9 leukocyte tethering or rolling GO:0050901 9.55 LEP TNF
10 negative regulation of glucose import GO:0046325 9.51 LEP TNF
11 negative regulation of lipid storage GO:0010888 9.43 LEP TNF
12 feeding behavior GO:0007631 9.43 HCRT HCRTR1 HCRTR2
13 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.37 HCRTR1 HCRTR2
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.32 HLA-DQB1 HLA-DRB1
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
16 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
17 antigen processing and presentation GO:0019882 8.92 CTSH HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 orexin receptor activity GO:0016499 8.96 HCRTR1 HCRTR2
3 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....